Vertex Pharmaceuticals Incorporated (VRTX)
USD 451.61
(-4.85%)
USD 451.61
(-4.85%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 4.3 Billion USD | -12.94% |
| 2022 | 4.3 Billion USD | 54.83% |
| 2021 | 2.78 Billion USD | -2.6% |
| 2020 | 2.85 Billion USD | 138.51% |
| 2019 | 1.19 Billion USD | 88.55% |
| 2018 | 635.15 Million USD | 415.36% |
| 2017 | 123.24 Million USD | 1140.37% |
| 2016 | 9.93 Million USD | 102.12% |
| 2015 | -468.66 Million USD | 32.31% |
| 2014 | -692.41 Million USD | 23.36% |
| 2013 | -903.44 Million USD | -38841.34% |
| 2012 | 2.33 Million USD | -97.95% |
| 2011 | 113.82 Million USD | 116.35% |
| 2010 | -696.07 Million USD | -13.48% |
| 2009 | -613.41 Million USD | -32.57% |
| 2008 | -462.7 Million USD | -10.22% |
| 2007 | -419.79 Million USD | -83.28% |
| 2006 | -229.03 Million USD | -52.82% |
| 2005 | -149.87 Million USD | 3.19% |
| 2004 | -154.8 Million USD | 41.48% |
| 2003 | -264.52 Million USD | -121.17% |
| 2002 | -119.6 Million USD | -30.28% |
| 2001 | -91.8 Million USD | -137.33% |
| 2000 | -38.68 Million USD | 2.32% |
| 1999 | -39.6 Million USD | -22.22% |
| 1998 | -32.4 Million USD | -68.75% |
| 1997 | -19.2 Million USD | 35.57% |
| 1996 | -29.8 Million USD | -12.45% |
| 1995 | -26.5 Million USD | -28.02% |
| 1994 | -20.7 Million USD | -1825.0% |
| 1993 | 1.2 Million USD | 112.0% |
| 1992 | -10 Million USD | -78.57% |
| 1991 | -5.6 Million USD | -36.59% |
| 1990 | -4.1 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 1.13 Billion USD | 18.48% |
| 2024 Q3 | 1.11 Billion USD | 131.67% |
| 2024 Q2 | -3.52 Billion USD | -410.31% |
| 2023 FY | 3.75 Billion USD | -12.94% |
| 2023 Q1 | 779 Million USD | -24.63% |
| 2023 Q2 | 1.02 Billion USD | 31.76% |
| 2023 Q4 | 958.8 Million USD | -7.64% |
| 2023 Q3 | 1.03 Billion USD | 1.14% |
| 2022 Q2 | 1.1 Billion USD | 6.28% |
| 2022 FY | 4.3 Billion USD | 54.83% |
| 2022 Q4 | 1.03 Billion USD | -8.27% |
| 2022 Q1 | 1.04 Billion USD | 18.59% |
| 2022 Q3 | 1.12 Billion USD | 1.84% |
| 2021 Q3 | 1.05 Billion USD | 2877.88% |
| 2021 FY | 2.78 Billion USD | -2.6% |
| 2021 Q1 | 887.82 Million USD | 19.04% |
| 2021 Q4 | 877.7 Million USD | -16.77% |
| 2021 Q2 | -37.96 Million USD | -104.28% |
| 2020 Q2 | 718.03 Million USD | -0.3% |
| 2020 Q1 | 720.22 Million USD | 30.6% |
| 2020 FY | 2.85 Billion USD | 138.51% |
| 2020 Q3 | 672.24 Million USD | -6.38% |
| 2020 Q4 | 745.79 Million USD | 10.94% |
| 2019 FY | 1.19 Billion USD | 88.55% |
| 2019 Q3 | 99.33 Million USD | -63.2% |
| 2019 Q2 | 269.96 Million USD | -2.47% |
| 2019 Q4 | 551.46 Million USD | 455.17% |
| 2019 Q1 | 276.8 Million USD | 116.73% |
| 2018 Q1 | 128.9 Million USD | 2.52% |
| 2018 Q2 | 172.87 Million USD | 34.12% |
| 2018 Q3 | 205.64 Million USD | 18.96% |
| 2018 FY | 635.15 Million USD | 415.36% |
| 2018 Q4 | 127.72 Million USD | -37.89% |
| 2017 Q4 | 125.73 Million USD | 138.56% |
| 2017 Q1 | 270.84 Million USD | 583.25% |
| 2017 Q2 | 52.7 Million USD | -80.54% |
| 2017 FY | 123.24 Million USD | 1140.37% |
| 2017 Q3 | -326.04 Million USD | -718.6% |
| 2016 Q2 | 3.35 Million USD | 123.4% |
| 2016 FY | 9.93 Million USD | 102.12% |
| 2016 Q4 | 39.64 Million USD | 282.45% |
| 2016 Q3 | -21.72 Million USD | -747.99% |
| 2016 Q1 | -14.33 Million USD | 74.17% |
| 2015 Q2 | -171.16 Million USD | 0.48% |
| 2015 Q4 | -55.48 Million USD | 20.76% |
| 2015 FY | -468.66 Million USD | 32.31% |
| 2015 Q3 | -70.02 Million USD | 59.09% |
| 2015 Q1 | -171.98 Million USD | -11.95% |
| 2014 Q4 | -153.62 Million USD | -8.03% |
| 2014 FY | -692.41 Million USD | 23.36% |
| 2014 Q2 | -180.83 Million USD | 16.43% |
| 2014 Q1 | -216.38 Million USD | 21.07% |
| 2014 Q3 | -142.2 Million USD | 21.36% |
| 2013 Q1 | -438.28 Million USD | -465.71% |
| 2013 FY | -903.44 Million USD | -38841.34% |
| 2013 Q4 | -274.16 Million USD | -104.51% |
| 2013 Q2 | -56.93 Million USD | 87.01% |
| 2013 Q3 | -134.05 Million USD | -135.47% |
| 2012 Q1 | 91.64 Million USD | -59.07% |
| 2012 Q2 | -10.77 Million USD | -111.75% |
| 2012 FY | 2.33 Million USD | -97.95% |
| 2012 Q3 | -1.07 Million USD | 90.06% |
| 2012 Q4 | -77.47 Million USD | -7133.99% |
| 2011 Q2 | -165.89 Million USD | -3.75% |
| 2011 Q3 | 215.7 Million USD | 230.03% |
| 2011 Q4 | 223.9 Million USD | 3.8% |
| 2011 FY | 113.82 Million USD | 116.35% |
| 2011 Q1 | -159.89 Million USD | 4.04% |
| 2010 Q2 | -169.57 Million USD | -5.8% |
| 2010 Q3 | -199.58 Million USD | -17.7% |
| 2010 FY | -696.07 Million USD | -13.48% |
| 2010 Q4 | -166.63 Million USD | 16.51% |
| 2010 Q1 | -160.28 Million USD | -9.24% |
| 2009 Q1 | -161.89 Million USD | -14.12% |
| 2009 Q3 | -148.23 Million USD | 5.68% |
| 2009 Q2 | -157.16 Million USD | 2.92% |
| 2009 FY | -613.41 Million USD | -32.57% |
| 2009 Q4 | -146.71 Million USD | 1.02% |
| 2008 FY | -462.7 Million USD | -10.22% |
| 2008 Q4 | -141.86 Million USD | -8.6% |
| 2008 Q3 | -130.62 Million USD | -42.79% |
| 2008 Q2 | -91.48 Million USD | 7.35% |
| 2008 Q1 | -98.73 Million USD | -7.62% |
| 2007 FY | -419.79 Million USD | -83.28% |
| 2007 Q2 | -125.62 Million USD | -41.74% |
| 2007 Q4 | -91.74 Million USD | 19.37% |
| 2007 Q3 | -113.79 Million USD | 9.41% |
| 2007 Q1 | -88.62 Million USD | -153.71% |
| 2006 FY | -229.03 Million USD | -52.82% |
| 2006 Q1 | -52.75 Million USD | -99.88% |
| 2006 Q4 | -34.93 Million USD | 43.77% |
| 2006 Q3 | -62.12 Million USD | 21.58% |
| 2006 Q2 | -79.22 Million USD | -50.17% |
| 2005 FY | -149.87 Million USD | 3.19% |
| 2005 Q4 | -26.39 Million USD | 37.87% |
| 2005 Q3 | -42.48 Million USD | -10.07% |
| 2005 Q2 | -38.59 Million USD | 8.97% |
| 2005 Q1 | -42.4 Million USD | -4.86% |
| 2004 FY | -154.8 Million USD | 41.48% |
| 2004 Q3 | -35.58 Million USD | 15.73% |
| 2004 Q1 | -36.54 Million USD | 66.62% |
| 2004 Q4 | -40.43 Million USD | -13.62% |
| 2004 Q2 | -42.23 Million USD | -15.56% |
| 2003 Q3 | -85.25 Million USD | 4.22% |
| 2003 Q2 | -89 Million USD | -563.43% |
| 2003 Q4 | -109.47 Million USD | -28.41% |
| 2003 FY | -264.52 Million USD | -121.17% |
| 2003 Q1 | 19.2 Million USD | 157.05% |
| 2002 Q1 | -26.06 Million USD | -67.89% |
| 2002 Q2 | -24.02 Million USD | 7.82% |
| 2002 FY | -119.6 Million USD | -30.28% |
| 2002 Q3 | -35.85 Million USD | -49.22% |
| 2002 Q4 | -33.66 Million USD | 6.1% |
| 2001 Q2 | -17.44 Million USD | -13.34% |
| 2001 Q1 | -15.39 Million USD | -6.9% |
| 2001 FY | -91.8 Million USD | -137.33% |
| 2001 Q4 | -15.52 Million USD | 57.06% |
| 2001 Q3 | -36.15 Million USD | -107.2% |
| 2000 Q1 | -18.56 Million USD | -983.86% |
| 2000 FY | -38.68 Million USD | 2.32% |
| 2000 Q4 | -14.4 Million USD | 5.08% |
| 2000 Q3 | -15.17 Million USD | -260.52% |
| 2000 Q2 | 9.45 Million USD | 150.92% |
| 1999 Q2 | -10.4 Million USD | 49.02% |
| 1999 Q3 | -13.9 Million USD | -33.65% |
| 1999 Q4 | 2.1 Million USD | 115.11% |
| 1999 FY | -39.6 Million USD | -22.22% |
| 1999 Q1 | -20.4 Million USD | -65.85% |
| 1998 Q2 | -9.6 Million USD | 21.95% |
| 1998 FY | -32.4 Million USD | -68.75% |
| 1998 Q1 | -12.3 Million USD | -89.23% |
| 1998 Q3 | -2.1 Million USD | 78.13% |
| 1998 Q4 | -12.3 Million USD | -485.71% |
| 1997 Q1 | -5.6 Million USD | -1.82% |
| 1997 Q2 | -1.2 Million USD | 78.57% |
| 1997 FY | -19.2 Million USD | 35.57% |
| 1997 Q4 | -6.5 Million USD | -14.04% |
| 1997 Q3 | -5.7 Million USD | -375.0% |
| 1996 FY | -29.8 Million USD | -12.45% |
| 1996 Q3 | -7.4 Million USD | 10.84% |
| 1996 Q2 | -8.3 Million USD | 3.49% |
| 1996 Q4 | -5.5 Million USD | 25.68% |
| 1996 Q1 | -8.6 Million USD | -273.91% |
| 1995 Q1 | -5.9 Million USD | 29.76% |
| 1995 Q4 | -2.3 Million USD | 71.25% |
| 1995 Q3 | -8 Million USD | 22.33% |
| 1995 Q2 | -10.3 Million USD | -74.58% |
| 1995 FY | -26.5 Million USD | -28.02% |
| 1994 Q3 | -3.8 Million USD | 29.63% |
| 1994 FY | -20.7 Million USD | -1825.0% |
| 1994 Q1 | -3.2 Million USD | -137.21% |
| 1994 Q2 | -5.4 Million USD | -68.75% |
| 1994 Q4 | -8.4 Million USD | -121.05% |
| 1993 Q4 | 8.6 Million USD | 396.55% |
| 1993 FY | 1.2 Million USD | 112.0% |
| 1993 Q1 | -3.5 Million USD | -20.69% |
| 1993 Q2 | -1 Million USD | 71.43% |
| 1993 Q3 | -2.9 Million USD | -190.0% |
| 1992 Q4 | -2.9 Million USD | -11.54% |
| 1992 Q2 | -2.3 Million USD | -9.52% |
| 1992 FY | -10 Million USD | -78.57% |
| 1992 Q1 | -2.1 Million USD | -23.53% |
| 1992 Q3 | -2.6 Million USD | -13.04% |
| 1991 FY | -5.6 Million USD | -36.59% |
| 1991 Q1 | 800 Thousand USD | 113.79% |
| 1991 Q3 | -1.4 Million USD | -7.69% |
| 1991 Q2 | -1.3 Million USD | -262.5% |
| 1991 Q4 | -1.7 Million USD | -21.43% |
| 1990 Q3 | 600 Thousand USD | 0.0% |
| 1990 Q1 | 500 Thousand USD | 0.0% |
| 1990 FY | -4.1 Million USD | 0.0% |
| 1990 Q4 | -5.8 Million USD | -1066.67% |
| 1990 Q2 | 600 Thousand USD | 20.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -237.2 Million USD | 1915.924% |
| Alkermes plc | 414.12 Million USD | -940.152% |
| Agenus Inc. | -159.54 Million USD | 2799.798% |
| Aptorum Group Limited | -10.52 Million USD | 41032.861% |
| Ardelyx, Inc. | -63.27 Million USD | 6907.478% |
| Dyadic International, Inc. | -8.22 Million USD | 52440.664% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | 361467.45% |
| Lantern Pharma Inc. | -17.87 Million USD | 24194.438% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | 21541.237% |
| Novavax, Inc. | -566.51 Million USD | 860.356% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 6002.383% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 5340.523% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | 22282.437% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | 40879.135% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | 8208.024% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 1232.075% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 17821.518% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | 11474.739% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 3439.458% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 5233.232% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 24659.553% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 9887.548% |
| Clearside Biomedical, Inc. | -24.84 Million USD | 17438.19% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 3198.23% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 1626.535% |
| AlloVir, Inc. | -181.33 Million USD | 2475.49% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 2201.199% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 14822.469% |
| Bicycle Therapeutics plc | -189.94 Million USD | 2367.75% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 2607.539% |
| ChromaDex Corporation | -5.59 Million USD | 77033.381% |
| Chimerix, Inc. | -93.06 Million USD | 4728.485% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 9655.807% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 3811.474% |
| CRISPR Therapeutics AG | -222.53 Million USD | 2035.624% |
| Precision BioSciences, Inc. | -43.73 Million USD | 9948.866% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 2361.024% |
| Fortress Biotech, Inc. | -142.34 Million USD | 3126.162% |
| Fortress Biotech, Inc. | -142.34 Million USD | 3126.162% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 4509.176% |
| ImmuCell Corporation | -5.74 Million USD | 75038.092% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 3304.294% |
| Immix Biopharma, Inc. | -16.14 Million USD | 26786.512% |
| Incyte Corporation | 620.52 Million USD | -594.17% |
| Innoviva, Inc. | 176.7 Million USD | -2337.623% |
| IO Biotech, Inc. | -91.44 Million USD | 4810.585% |
| Jaguar Health, Inc. | -34.29 Million USD | 12661.605% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 2634.703% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | -35970.173% |
| ContextLogic Inc. | -328 Million USD | 1413.262% |
| MiMedx Group, Inc. | 37.11 Million USD | -11505.507% |
| MEI Pharma, Inc. | 14.54 Million USD | -29521.098% |
| NextCure, Inc. | -67.63 Million USD | 6468.556% |
| Onconetix, Inc. | -36.03 Million USD | 12053.791% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | 10426.269% |
| Opthea Limited | -191.84 Million USD | 2345.329% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 156632.483% |
| Vaxcyte, Inc. | -468.04 Million USD | 1020.325% |
| PDS Biotechnology Corporation | -43.04 Million USD | 10106.915% |
| Precigen, Inc. | -88.92 Million USD | 4944.079% |
| Pharming Group N.V. | -4.87 Million USD | 88376.691% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 2674.531% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | 14576.072% |
| PureTech Health plc | -146.19 Million USD | 3046.327% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | 21121.424% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 1928.326% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 17821.518% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 1672.052% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | 14798.857% |
| Acelyrin, Inc. | -422.06 Million USD | 1120.58% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | 33404675.748% |
| Summit Therapeutics Inc. | -89.73 Million USD | 4900.192% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | 11721.789% |
| Senti Biosciences, Inc. | -92.72 Million USD | 4745.357% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 3853.06% |
| Elevation Oncology, Inc. | -45.44 Million USD | 9578.49% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | 12670.403% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | 109370.613% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | 136327.071% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | 13144.729% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 50770.509% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 6434.931% |
| Seer, Inc. | -103.46 Million USD | 4263.324% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | 6650.434% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 6088.211% |
| ESSA Pharma Inc. | -32.13 Million USD | 13504.761% |
| GlycoMimetics, Inc. | -39.27 Million USD | 11067.455% |
| GT Biopharma, Inc. | -13.57 Million USD | 31828.786% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 2064.912% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | 9412.305% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -4861.872% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 7689.105% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | 8463.103% |
| Alzamend Neuro, Inc. | -9.93 Million USD | 43445.279% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 954.129% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | 62545.636% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 8597.228% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 1758.906% |
| Aptose Biosciences Inc. | -52.35 Million USD | 8327.328% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | 29970.103% |
| Soligenix, Inc. | -7.69 Million USD | 56056.529% |
| Century Therapeutics, Inc. | -146.54 Million USD | 3039.35% |
| Kura Oncology, Inc. | -165.8 Million USD | 2697.947% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 4709.022% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | 51879.06% |
| Ocean Biomedical, Inc. | -2.48 Million USD | 173674.803% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | 66532.758% |
| Autolus Therapeutics plc | -195.02 Million USD | 2308.657% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 5188.179% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 5947.656% |
| Eterna Therapeutics Inc. | -21.13 Million USD | 20480.885% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 1997.285% |
| GRI Bio, Inc. | -11.38 Million USD | 37928.225% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 95489.102% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 3383.331% |
| IGM Biosciences, Inc. | -263.46 Million USD | 1734.967% |
| INmune Bio, Inc. | -29.74 Million USD | 14583.373% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 3994.137% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 11413.103% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 27056.647% |
| Entero Therapeutics, Inc. | -15.77 Million USD | 27413.089% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | 7150.149% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 4106.157% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 1660.654% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 2219.843% |
| Verastem, Inc. | -92.08 Million USD | 4777.794% |
| Abeona Therapeutics Inc. | -47.13 Million USD | 9238.644% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 2439.189% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 3738.706% |
| Histogen Inc. | -10.64 Million USD | 40572.611% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | 27940.687% |
| Surrozen, Inc. | -45.78 Million USD | 9509.131% |
| Organovo Holdings, Inc. | -15.08 Million USD | 28652.963% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 84722.795% |
| Ovid Therapeutics Inc. | -59.28 Million USD | 7366.184% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 8497.668% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | 17139.161% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | 56533.756% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 2614.844% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | 8990.984% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 5607.96% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | 28400.138% |
| Apollomics, Inc. | -54.83 Million USD | 7955.528% |
| Amarin Corporation plc | -67.58 Million USD | 6473.173% |
| Mesoblast Limited | -58.79 Million USD | 7426.428% |
| Turnstone Biologics Corp. | -59.03 Million USD | 7396.89% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 2702.247% |
| Synaptogenix, Inc. | -8.31 Million USD | 51911.11% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | 29631.743% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 4797.844% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 89999.417% |
| Monopar Therapeutics Inc. | -8.83 Million USD | 48875.737% |
| Exelixis, Inc. | 170.88 Million USD | -2420.701% |
| Better Therapeutics, Inc. | -38.26 Million USD | 11357.906% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 2877.903% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 932.977% |
| NLS Pharmaceutics AG | -11.8 Million USD | 36582.4% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | 53663.173% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 14461.684% |
| Gritstone bio, Inc. | -154.63 Million USD | 2885.61% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 6355.355% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | 25256.146% |
| Avid Bioservices, Inc. | -18.67 Million USD | 23161.891% |
| Insmed Incorporated | -709.62 Million USD | 707.01% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | 27554.163% |
| MediWound Ltd. | -15.29 Million USD | 28272.008% |
| OmniAb, Inc. | -69.41 Million USD | 6305.074% |
| Alector, Inc. | -151.74 Million USD | 2938.737% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 4089.054% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 8360.144% |
| Zai Lab Limited | -366.57 Million USD | 1275.073% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 1459.789% |
| Aura Biosciences, Inc. | -84.99 Million USD | 5168.184% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 1854.59% |
| Immunic, Inc. | -99.22 Million USD | 4441.231% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 3108.913% |
| Veracyte, Inc. | -85.79 Million USD | 5120.689% |
| InMed Pharmaceuticals Inc. | - USD | -Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 1628.485% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 30413.16% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | 62636.776% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | 23021.236% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | -644.495% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | 17023.349% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | -11001.232% |
| TG Therapeutics, Inc. | 20.63 Million USD | -20776.751% |
| Galecto, Inc. | -39.9 Million USD | 10894.387% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 10337.914% |
| Fortrea Holdings Inc. | 63.1 Million USD | -6726.466% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 3167.037% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | 15016.199% |
| XBiotech Inc. | -37.51 Million USD | 11583.604% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 6355.355% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | 6517.61% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 4091.9% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 16878.981% |
| Theravance Biopharma, Inc. | -53.29 Million USD | 8182.827% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 856.753% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 5587.82% |
| Vaxxinity, Inc. | -58.28 Million USD | 7490.409% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 4253.449% |
| Gain Therapeutics, Inc. | -22.25 Million USD | 19456.825% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 5084.609% |
| NexImmune, Inc. | -29.19 Million USD | 14855.512% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | 76744.107% |
| Marker Therapeutics, Inc. | -14.58 Million USD | 29641.104% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | -6.434% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | 17019.361% |
| Scopus BioPharma Inc. | -11.71 Million USD | 36869.486% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 3490.077% |
| Ainos, Inc. | -13.2 Million USD | 32716.771% |
| Pluri Inc. | -22.15 Million USD | 19539.931% |
| Prothena Corporation plc | -191.03 Million USD | 2354.811% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 3220.518% |
| Celularity Inc. | -192.28 Million USD | 2340.141% |
| Rallybio Corporation | -78.93 Million USD | 5557.229% |
| Cue Biopharma, Inc. | -52.14 Million USD | 8359.986% |
| MeiraGTx Holdings plc | -137.06 Million USD | 3242.761% |
| Omeros Corporation | -164.53 Million USD | 2718.064% |
| Humacyte, Inc. | -100.04 Million USD | 4405.476% |
| Immunocore Holdings plc | -59.64 Million USD | 7321.412% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | 23309.763% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | 17693.841% |
| Blueprint Medicines Corporation | -486.27 Million USD | 985.812% |
| CalciMedica, Inc. | -21.87 Million USD | 19791.429% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 5869.488% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 3376.039% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 2614.668% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 1417.681% |
| Pulmatrix, Inc. | -14.74 Million USD | 29323.202% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | 12150.636% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 4947.186% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 935.935% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | 6476.664% |
| Cytokinetics, Incorporated | -496.2 Million USD | 968.089% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 12614.89% |
| Nutriband Inc. | -4.87 Million USD | 88514.726% |
| Protara Therapeutics, Inc. | -43.61 Million USD | 9976.642% |
| Vor Biopharma Inc. | -126.03 Million USD | 3517.674% |
| Roivant Sciences Ltd. | 4.24 Billion USD | -1.544% |
| Evogene Ltd. | -26.39 Million USD | 16421.852% |
| ProKidney Corp. | -151.52 Million USD | 2942.822% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 6774.673% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | 56097.978% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 809.205% |
| CorMedix Inc. | -48.95 Million USD | 8898.396% |
| BioLineRx Ltd. | -49.69 Million USD | 8768.048% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 3872.783% |
| Galectin Therapeutics Inc. | -38.07 Million USD | 11414.089% |
| Atai Life Sciences N.V. | -125.47 Million USD | 3533.064% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 5376.258% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 5391.184% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 1830.003% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 14112.687% |
| MediciNova, Inc. | -9.9 Million USD | 43608.936% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 3508.56% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 59575.656% |
| GeoVax Labs, Inc. | -26.74 Million USD | 16207.055% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 1958.083% |
| Biomea Fusion, Inc. | -126.13 Million USD | 3514.992% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 1332.821% |
| Mereo BioPharma Group plc | -28.41 Million USD | 15258.713% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 2354.185% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 1973.201% |
| Absci Corporation | -115.51 Million USD | 3828.953% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 15714.239% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 3916.439% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 1878.768% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | 17195.968% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 2170.973% |
| Allakos Inc. | -196.05 Million USD | 2297.076% |
| Imunon, Inc. | -21.03 Million USD | 20582.225% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 3992.413% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -3915.119% |
| BioAtla, Inc. | -129.68 Million USD | 3421.459% |
| NLS Pharmaceutics AG | -11.8 Million USD | 36582.4% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 27288.664% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 1414.316% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | 10415.389% |
| XOMA Corporation | -41.84 Million USD | 10393.204% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 4193.142% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 3645.413% |
| aTyr Pharma, Inc. | -54.91 Million USD | 7943.369% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 5026.968% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 2591.757% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 1792.867% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | 20166.617% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | 52548.904% |
| Akari Therapeutics, Plc | -16.8 Million USD | 25730.727% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 48710779.484% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | -1176.017% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 66024.174% |
| UroGen Pharma Ltd. | -65.53 Million USD | 6672.723% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 4924.817% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 59407.351% |
| Orgenesis Inc. | -53.63 Million USD | 8130.987% |
| Entera Bio Ltd. | -8.89 Million USD | 48547.869% |
| GH Research PLC | -41.22 Million USD | 10549.517% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | 16855.485% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 5286.447% |
| Xencor, Inc. | -138.63 Million USD | 3206.99% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | 83666.411% |
| Replimune Group, Inc. | -234.77 Million USD | 1934.751% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | 20143.162% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | 30973.71% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 66024.174% |
| Portage Biotech Inc. | -18.25 Million USD | 23698.86% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 59575.656% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 4203.905% |
| OncoCyte Corporation | -25.13 Million USD | 17236.776% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 38203.091% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 37696.902% |
| Purple Biotech Ltd. | 22.27 Million USD | -19241.296% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | 57441.587% |
| scPharmaceuticals Inc. | -55.39 Million USD | 7875.832% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | 22893.788% |
| HilleVax, Inc. | -133.34 Million USD | 3330.342% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | 35849.855% |
| Tharimmune, Inc. | -9.45 Million USD | 45656.846% |
| Genprex, Inc. | -31.07 Million USD | 13961.371% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 2388.861% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | 13828.209% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | 563171.895% |
| Virios Therapeutics, Inc. | -5.44 Million USD | 79181.404% |
| OKYO Pharma Limited | -15.74 Thousand USD | 27349775.201% |
| Savara Inc. | -60 Million USD | 7278.329% |
| Curis, Inc. | -48.33 Million USD | 9012.315% |
| Daré Bioscience, Inc. | -30.83 Million USD | 14067.305% |
| Carmell Therapeutics Corporation | -5.21 Million USD | 82662.178% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | 59293.349% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | 15907.339% |
| BeiGene, Ltd. | -1.2 Billion USD | 456.659% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 21703.065% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 984.161% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 4699.475% |
| Erasca, Inc. | -141.52 Million USD | 3143.632% |
| bluebird bio, Inc. | -244.26 Million USD | 1863.475% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 95251.861% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | -2115.325% |
| DBV Technologies S.A. | -76.43 Million USD | 5735.728% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 95251.861% |
| Moderna, Inc. | -4.23 Billion USD | 201.616% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 10209.367% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | 67827.987% |
| Molecular Templates, Inc. | -10.46 Million USD | 41257.08% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | 6506.443% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 1243.349% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 3105.701% |
| Spruce Biosciences, Inc. | -51.99 Million USD | 8384.769% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 2887.268% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 2169.62% |
| MacroGenics, Inc. | -168.24 Million USD | 2660.27% |
| RenovoRx, Inc. | -11.39 Million USD | 37898.35% |
| Adicet Bio, Inc. | -152.03 Million USD | 2933.173% |
| Prime Medicine, Inc. | -191.29 Million USD | 2351.793% |
| Aditxt, Inc. | -26.06 Million USD | 16627.625% |
| Adagene Inc. | -23.71 Million USD | 18259.883% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 59025.339% |
| Quantum-Si incorporated | -111.17 Million USD | 3974.662% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | 13710.655% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 29648.419% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | -3430.333% |
| SciSparc Ltd. | -5.77 Million USD | 74714.585% |
| Vericel Corporation | -6.46 Million USD | 66738.304% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 49859.353% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | 18731.397% |
| Generation Bio Co. | -138.56 Million USD | 3208.694% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 5287.884% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 5082.073% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 1886.596% |
| Invivyd, Inc. | -207.78 Million USD | 2173.076% |
| Relay Therapeutics, Inc. | -373 Million USD | 1254.826% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | 46029.5% |
| Spero Therapeutics, Inc. | 21.48 Million USD | -19952.605% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 41973.238% |
| 2seventy bio, Inc. | -216.7 Million USD | 2087.744% |
| ADMA Biologics, Inc. | 21.63 Million USD | -19812.629% |
| Clene Inc. | -40.54 Million USD | 10725.308% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | 17989.88% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | 7960.975% |
| GeoVax Labs, Inc. | -26.74 Million USD | 16207.055% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 1330.503% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | 11826.826% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | -26692.934% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 4253.729% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 12768.372% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 2629.687% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 729.471% |
| Evaxion Biotech A/S | -22.19 Million USD | 19505.776% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 5328.691% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 2030.541% |
| Trevena, Inc. | -35.28 Million USD | 12306.699% |
| Surrozen, Inc. | -45.78 Million USD | 9509.131% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 5488.079% |
| Cingulate Inc. | -22.75 Million USD | 19026.42% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | -57394.661% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 9743.585% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | 52413.953% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 4300.062% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 5970.208% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | 7039.298% |
| Clearmind Medicine Inc. | -8.74 Million USD | 49377.285% |
| Kronos Bio, Inc. | -121.83 Million USD | 3635.664% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 5753.184% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 146964.031% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 4372.169% |
| Statera Biopharma, Inc. | -98.34 Million USD | 4480.042% |
| ImmunityBio, Inc. | -362.25 Million USD | 1289.096% |
| Korro Bio, Inc. | -84.53 Million USD | 5195.583% |
| Kineta, Inc. | -15.72 Million USD | 27496.171% |
| BioVie Inc. | -32.17 Million USD | 13485.816% |
| Codexis, Inc. | -68.06 Million USD | 6428.138% |
| Celularity Inc. | -192.28 Million USD | 2340.141% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 2035.016% |
| Celcuity Inc. | -66.23 Million USD | 6603.818% |
| Virax Biolabs Group Limited | -6.49 Million USD | 66405.209% |
| Cibus, Inc. | -318.88 Million USD | 1450.809% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | 10117.442% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 12827.514% |
| IN8bio, Inc. | -30.33 Million USD | 14298.833% |
| Kodiak Sciences Inc. | -277.32 Million USD | 1653.254% |
| Annexon, Inc. | -143.72 Million USD | 3097.085% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 3579.655% |
| Assembly Biosciences, Inc. | -64.64 Million USD | 6763.212% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | 18473.571% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 1317.737% |
| Eyenovia, Inc. | -25.4 Million USD | 17054.359% |
| Puma Biotechnology, Inc. | 32.64 Million USD | -13096.998% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 77545.164% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 5543.367% |
| Arcellx, Inc. | -89.88 Million USD | 4892.501% |
| Cardiff Oncology, Inc. | -45.41 Million USD | 9585.378% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 3239.417% |
| Regulus Therapeutics Inc. | -31.1 Million USD | 13946.475% |
| Moolec Science SA | -6.65 Million USD | 64837.395% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | 7145.536% |
| Geron Corporation | -193.94 Million USD | 2321.002% |
| LAVA Therapeutics N.V. | -43.25 Million USD | 10058.847% |
| Royalty Pharma plc | 1.49 Billion USD | -188.677% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 2723.932% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 46278.837% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | 19773.745% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 2619.639% |
| Humacyte, Inc. | -100.04 Million USD | 4405.476% |
| Structure Therapeutics Inc. | -102.77 Million USD | 4291.194% |
| 89bio, Inc. | -151.2 Million USD | 2948.8% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 5475.505% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | 29725.172% |
| Genelux Corporation | -24.16 Million USD | 17925.367% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | 12797.875% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 2608.006% |
| Notable Labs, Ltd. | -14.65 Million USD | 29488.688% |
| Liquidia Corporation | -73.38 Million USD | 5969.808% |
| Mustang Bio, Inc. | -50.72 Million USD | 8591.701% |
| Immunovant, Inc. | -282.7 Million USD | 1623.652% |
| Quantum-Si incorporated | -111.17 Million USD | 3974.662% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 5615.153% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | 20354.385% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 4322.542% |
| Acasti Pharma Inc. | -11.31 Million USD | 38179.031% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | 18892.724% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 27056.647% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 2112.343% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | 117500.258% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 27215.07% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | 14873.468% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | 10508.612% |
| PepGen Inc. | -84.76 Million USD | 5181.637% |
| Moleculin Biotech, Inc. | -29.63 Million USD | 14637.14% |
| United Therapeutics Corporation | 1.18 Billion USD | -263.533% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 18912.508% |
| Solid Biosciences Inc. | -104.31 Million USD | 4229.32% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | 13229.373% |
| Immuneering Corporation | -58.41 Million USD | 7474.229% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 84722.795% |
| Silo Pharma, Inc. | -3.85 Million USD | 111820.846% |
| Belite Bio, Inc | -31.66 Million USD | 13702.059% |
| XOMA Corporation | -41.84 Million USD | 10393.204% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | 6479.591% |
| Bionomics Limited | -17.89 Billion USD | 124.074% |
| Apogee Therapeutics, Inc. | -93 Million USD | 4731.571% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -11972.59% |
| uniQure N.V. | -282.87 Million USD | 1622.779% |
| Cassava Sciences, Inc. | -105.95 Million USD | 4165.328% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 59025.339% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 3426.152% |
| Forte Biosciences, Inc. | -32.48 Million USD | 13359.558% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | 51942.905% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | 14753.853% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 77545.164% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 30413.16% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | 48558.769% |
| Altimmune, Inc. | -95.92 Million USD | 4590.3% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 5961.023% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -11972.59% |
| Compugen Ltd. | -12.99 Million USD | 33255.018% |
| Peak Bio, Inc. | -1356.23 USD | 317608470.262% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | 8783.776% |
| Benitec Biopharma Inc. | -22.49 Million USD | 19252.957% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 1877.733% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | 14580.939% |
| Zura Bio Limited | -62.63 Million USD | 6976.816% |
| PolyPid Ltd. | -22.86 Million USD | 18937.189% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | 26565.348% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | 14580.939% |
| Instil Bio, Inc. | -159.16 Million USD | 2806.243% |
| argenx SE | -425.04 Million USD | 1113.413% |
| Immunome, Inc. | -109.53 Million USD | 4032.712% |
| Compass Therapeutics, Inc. | -50.36 Million USD | 8652.906% |
| Verona Pharma plc | -67.83 Million USD | 6450.351% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | 16629.163% |
| Shattuck Labs, Inc. | -91.95 Million USD | 4784.255% |
| CervoMed Inc. | -7.81 Million USD | 55233.212% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 5991.807% |
| Plus Therapeutics, Inc. | -13.32 Million USD | 32436.161% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 9041.545% |
| Moolec Science SA | -6.65 Million USD | 64837.395% |
| Enveric Biosciences, Inc. | -16.44 Million USD | 26287.894% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 3285.393% |
| AnaptysBio, Inc. | -164.41 Million USD | 2719.959% |
| Design Therapeutics, Inc. | -78.19 Million USD | 5609.016% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 5048.817% |
| NeurAxis, Inc. | -6.66 Million USD | 64733.554% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | 10736.065% |
| Lumos Pharma, Inc. | -36.61 Million USD | 11864.626% |
| Achilles Therapeutics plc | -75.25 Million USD | 5823.872% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | 16629.163% |
| 180 Life Sciences Corp. | -13.47 Million USD | 32060.675% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | -83438.406% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 146964.031% |
| Nutriband Inc. | -4.87 Million USD | 88514.726% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 3988.337% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | 7868.4% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | 8573.326% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | 6616.74% |
| MoonLake Immunotherapeutics | -54.12 Million USD | 8058.71% |
| Palisade Bio, Inc. | -13.07 Million USD | 33057.154% |
| Tourmaline Bio, Inc. | -45.4 Million USD | 9586.005% |
| Beam Therapeutics Inc. | -176.48 Million USD | 2540.717% |
| Neurogene Inc. | -55.58 Million USD | 7849.672% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 4046.259% |
| AEON Biopharma, Inc. | -48.42 Million USD | 8994.464% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 4554.038% |
| Sesen Bio, Inc. | -25.9 Million USD | 16725.497% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 5256.892% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | 34322.099% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 1035.276% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 6046.382% |
| Athira Pharma, Inc. | -125.46 Million USD | 3533.201% |
| Vaccinex, Inc. | -22.88 Million USD | 18922.373% |
| HCW Biologics Inc. | -25.71 Million USD | 16849.517% |
| XOMA Corporation | -41.84 Million USD | 10393.204% |
| Nektar Therapeutics | -137.42 Million USD | 3234.437% |
| Arvinas, Inc. | -401.5 Million USD | 1172.852% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 48710779.484% |
| Merus N.V. | -156.54 Million USD | 2851.57% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 4396.287% |
| Quince Therapeutics, Inc. | -34.62 Million USD | 12542.23% |
| Rezolute, Inc. | -70.42 Million USD | 6216.61% |
| Clene Inc. | -40.54 Million USD | 10725.308% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | 26399.764% |
| BeyondSpring Inc. | -23.11 Million USD | 18735.892% |
| Synlogic, Inc. | -55.16 Million USD | 7908.959% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | 24125.322% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 39895.824% |
| Peak Bio, Inc. | -1356.23 USD | 317608470.262% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | 10735.015% |
| Krystal Biotech, Inc. | -109.72 Million USD | 4025.652% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 3425.228% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 1355.783% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | 90861.539% |
| MannKind Corporation | 8.67 Million USD | -49537.013% |
| Ikena Oncology, Inc. | -75.41 Million USD | 5811.577% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | 44751.187% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | 6507.11% |
| Gossamer Bio, Inc. | -183.75 Million USD | 2444.103% |
| CohBar, Inc. | -12.38 Million USD | 34870.719% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | 8592.035% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 15714.239% |
| Legend Biotech Corporation | -439.48 Million USD | 1080.124% |
| Mural Oncology plc | -194.63 Million USD | 2313.083% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 6515.412% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 26779.641% |
| Disc Medicine, Inc. | -91.12 Million USD | 4827.023% |
| Champions Oncology, Inc. | -7.35 Million USD | 58657.64% |
| REGENXBIO Inc. | -268.12 Million USD | 1706.509% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 40288.7% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 7825.626% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | 11156.029% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 3866.713% |
| Vaxart, Inc. | -83.34 Million USD | 5268.152% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | 50657.464% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | 10165.644% |
| Cellectis S.A. | -106.62 Million USD | 4139.821% |
| Longeveron Inc. | -21.02 Million USD | 20583.618% |
| Repare Therapeutics Inc. | -116.22 Million USD | 3806.205% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 1708.332% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 5794.362% |
| Revolution Medicines, Inc. | -487.18 Million USD | 984.161% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | 64854.961% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | 9900.018% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 5874.903% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 6285.826% |
| Anixa Biosciences, Inc. | -11.01 Million USD | 39219.971% |
| Denali Therapeutics Inc. | -196.69 Million USD | 2289.894% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 49859.353% |
| Veru Inc. | -93.78 Million USD | 4693.088% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | 18564.143% |
| Cingulate Inc. | -22.75 Million USD | 19026.42% |
| Passage Bio, Inc. | -108.38 Million USD | 4074.112% |
| Context Therapeutics Inc. | -25.07 Million USD | 17280.098% |
| Exicure, Inc. | -14.99 Million USD | 28824.326% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 2190.37% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | 10710.129% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | 44429.813% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 2436.499% |
| Nuvalent, Inc. | -149.49 Million USD | 2981.425% |
| ABVC BioPharma, Inc. | -8.21 Million USD | 52524.941% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 4954.56% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | 20835.053% |
| OmniAb, Inc. | -69.41 Million USD | 6305.074% |
| Anew Medical, Inc. | -1.3 Million USD | 331232.192% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | 33828.76% |
| Lipocine Inc. | -17.93 Million USD | 24122.7% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 6387.128% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 5756.45% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 11413.103% |
| G1 Therapeutics, Inc. | -39.52 Million USD | 10997.614% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | 19343.656% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 842.866% |
| Ocugen, Inc. | -65.53 Million USD | 6673.225% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 4688.989% |
| Q32 Bio Inc. | -92.1 Million USD | 4776.88% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | 20191.889% |
| Alumis Inc. Common Stock | -158.17 Million USD | 2823.267% |
| Equillium, Inc. | -14.52 Million USD | 29761.892% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | 7002.381% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 54602.212% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 22933.158% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 9274.458% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 4071.291% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 36085.753% |
| Dominari Holdings Inc. | -21.79 Million USD | 19862.801% |
| Edesa Biotech, Inc. | -9.22 Million USD | 46805.118% |
| vTv Therapeutics Inc. | -25.5 Million USD | 16990.832% |
| Bio-Techne Corporation | 206.68 Million USD | -1984.079% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 1200.292% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | -2143.139% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 3356.424% |
| Candel Therapeutics, Inc. | -38.39 Million USD | 11320.078% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 2950.742% |
| Nkarta, Inc. | -131.65 Million USD | 3371.933% |
| BioCardia, Inc. | -11.64 Million USD | 37093.301% |
| Iterum Therapeutics plc | -47.46 Million USD | 9174.534% |